Prostate Cancer - Results from #340

Barriers and facilitators of the application of precision medicine to the genitourinary cancer care pathway: Perspective from a low- and middle- income country in sub-Saharan Africa. August 28, 2024

The impact of neoadjuvant relugolix on multi-dimensional patient-reported fatigue. August 28, 2024

Cost-utility Analysis of Navigate, a Treatment Decision Aid for Men with Prostate Cancer and Their Partners, in Comparison to Usual Care. August 28, 2024

18F-Flotufolastat Positron Emission Tomography in African American Patients With Suspected Prostate Cancer Recurrence: Findings From the Phase 3 SPOTLIGHT Study. August 28, 2024

Neighborhood greenness and long-term physical and psychosocial quality of life among prostate cancer survivors in the Health Professionals Follow-up Study. August 28, 2024

Proficiency score as a predictor of early trifecta achievement during the learning curve of robot-assisted radical prostatectomy for high-risk prostate cancer: Results of a multicentric series. August 27, 2024

DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes. August 27, 2024

Assessing olaparib efficacy in U.S. Veterans with metastatic prostate cancer utilizing a time-indifferent g-rate method ideal for real-world analyses. August 27, 2024

Epigenetic profiling of prostate cancer reveals potential prognostic signatures. August 27, 2024

The learning curve for transperineal MRI/TRUS fusion prostate biopsy: A prospective evaluation of a stepwise approach. August 27, 2024

Identification of long noncoding RNAs with aberrant expression in prostate cancer metastases. August 27, 2024

Multiparametric Ultrasound Imaging of Prostate Cancer Using Deep Neural Networks. August 26, 2024

The association of type and number of high-risk criteria with cancer-specific mortality in prostate cancer patients treated with radical prostatectomy. August 26, 2024

Development and validation of a novel nomogram to avoid unnecessary biopsy in patients with PI-RADS category ≥ 4 lesions and PSA ≤ 20 ng/ml. August 26, 2024

Genomic and epigenomic analysis of plasma cell-free DNA identifies stemness features associated with worse survival in lethal prostate cancer. August 26, 2024

Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer. August 26, 2024

Trends in Active Surveillance for Men With Intermediate-Risk Prostate Cancer. August 23, 2024

Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled Trial. August 23, 2024

Patient Preferences for Attributes of Androgen Deprivation Therapies in Prostate Cancer: A Discrete Choice Experiment with Latent Class Analysis. August 23, 2024

How Can Participant Experience of Quality-of-Life Research Be Improved in Cancer Research: Views of the Patient and Public Involvement Representatives from the STAMPEDE2 Prostate Cancer Trial. August 23, 2024

Page 18 of 1435